考格列汀临床应用专家指导意见
Expert opinion on clinical application of Cofrogliptin tablets
《考格列汀临床应用专家指导意见》专家组 母义明 单忠艳
摘要
二肽基肽酶4(DPP-4)抑制剂疗效和安全性良好,对体重影响中性,绝大多数为口服每日一次,使用简便,已成为新诊断2型糖尿病和老年糖尿病患者的优选降糖药物之一.新型超长效DPP-4抑制剂考格列汀口服每2周1次,在保障疗效和安全性的同时,可进一步提高患者治疗依从性.文章对考格列汀的适用人群、使用方法、在特殊人群中使用的注意事项等提出指导建议,为临床提供参考.
Abstract
Dipeptidyl peptidase-4(DPP-4)inhibitors is effective,safe,and body-weight neutral.Most of them areorally administered once a day.DPP-4 inhibitor has become one of the preferred options for newly diagnosed type 2 diabetes and elderly diabetes patients.The novel ultralong-acting DPP-4 inhibitor,Cofrogliptin,is orally administered once every 2 weeks.While ensuring efficacy and safety,it can further improve compliance.This article provides suggestions on the suitable population,usage,and cautions in special populations for Cofrogliptin,in order to providing reference for clinical practice.
关键词
2型糖尿病/专家建议/二肽基肽酶4抑制剂,超长效/考格列汀Key words
type 2 diabetes/expert opinion/dipeptidyl peptidase-4 inhibitors,ultralong-acting/Cofrogliptin引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据